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EmpyemaAbstract Background: Thoracic empyema (TE) and loculated parapneumonic effusions (CPE)
cause considerable morbidity and mortality, with an estimated case-fatality rate of 15%. Intrapleu-
ral administration of recombinant tissue plasminogen activators (r-TPA) such as tenecteplase
(TNKase) has been recently employed to lyse the ﬁbrinous structures of multiloculated pleural
space with reduction of surgical intervention. Yet, there is no enough data concerning intrapleural
TNKase in treating patients with CPE or TE. Thus, the objective of this study is to determine the
safety and efﬁcacy of TNKase for the treatment of loculated parapneumonic pleural effusions and
thoracic empyema after failure of complete drainage using pigtail catheter.
Patients and methods: This study was done at Respirology and Interventional Radiology
Departments, Farwaniya Hospital, Alrashid Respiratory Centre and Thoracic Surgery Department,
Chest Hospital, Ministry of Health, State of Kuwait, between January 2012 and November 2013. 58
patients were admitted with loculated pleural effusions {22 patients (37.9%) with thoracic empyema
and 36 patients (62.1%) with complicated parapneumonic effusion}. All patients received intrapleu-
ral TNKase after failure of complete drainage of pigtail catheter, which was inserted under chest
ultrasound guidance. The evaluation was made according to imaging, laboratory, and clinical sta-
tus. Adverse effects and hemorrhagic complications were also reported.
Results: The overall intrapleural TNKase effectiveness in achieving complete drainage of pleural
collections was 49 of 58 cases (84.5%). Intrapleural TNKase was successful in 70% (14 of 20) of
patients with TE, and 92.1% (35 of 38) of patients with CPE. The total number of TNKase instil-
lations ranged from 2 to 5 (mean, 3.2). The mean volume of pleural ﬂuid increased signiﬁcantly after
914 A. Refaat et al.TNKase administration (P< 0.001). White blood cell count (WBC) and C-reactive protein (CRP)
were signiﬁcantly improved after TNKase instillations (both P< 0.05). Complications observed
were mild and local bleeding occurred in only 4 patients (6.9%).
Conclusion: Intrapleural TNKase is an effective therapy in improving drainage of loculated CPE
and TE not drained with pigtail catheters alone and can prevent surgical interventions. Intrapleural
TNKase is well tolerated with infrequent adverse events.
ª 2014 Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest Diseases and
Tuberculosis. Open access under CC BY-NC-ND license.Introduction
Loculated pleural effusions, arising from infection, malig-
nancy, and/or hemothoraces, are common sources of morbid-
ity and mortality for hospitalized patients and remain a
common clinical problem with an often protracted course [1].
In Thoracic empyema (TE) and complicated parapneumonic
effusions (CPE), white blood cells release permeable factors
causing ﬁbrinogen to spill into the pleural space. The ﬁbrino-
gen is then converted to ﬁbrin that can trap the causative
microorganism. This entrapment will prevent the antibiotics
from reaching the site of infection [2].
The traditional treatment of pleural drainage via chest tube
has been associated with a high failure rate because of the
inability to drain loculated areas. These patients traditionally
required open surgical decortication [3]. The advent of the
minimally invasive video-assisted thoracoscopic surgery
(VATS), with low operative morbidity, has become the gold
standard for most operative managements [4]. However, due
to the invasiveness and complexity of these procedures, there
has been a necessity for less invasive methods for cases not
responding to standard chest tube drainage.
The pathogenesis of ﬁbrin deposition is thought to be a
result of alterations in the balance of procoagulant and ﬁbrino-
lytic activity; therefore ﬁbrinolytics have been used to promote
pleural drainage in these complex pleural processes. Intrapleu-
ral administration of streptokinase has been perplexing as a
result of the development of antibodies as well as the develop-
ment of delayed hypersensitivity reaction [5]. Thus, urokinase
was introduced to alleviate those issues seen with streptoki-
nase, but there were reported cases of allergic reactions and
potential risk of viral transmission [6]. This evolved into the
development of alteplase and Tenecteplase (TNKase), which
are recombinant tissue plasminogen activators (r-tPAs), pro-
duced by recombinant DNA technology, that could be a more
appropriate therapeutic agent. This may be secondary to a
decreased level of endogenous tPA in pleural ﬂuid or because
of inhibition of plasminogen and plasmin by plasminogen acti-
vator inhibitors-1 and -2 and other mediators [7]. Tenecteplase
is a ﬁbrin speciﬁc ﬁbrinolytic. It is different from human tissue
plasminogen activator by having three amino acid substitu-
tions. These substitutions increase ﬁbrin binding, increase
resistance to plasminogen activator inhibitor-1, and can break
up the ﬁbrinous debris, thereby allowing drainage of the ﬂuid
[8].
Despite extensive use of intrapleural ﬁbrinolytics in recent
years in the treatment of complicated pleural effusions to lyse
loculations and promote resolution [9–11], little is known
about complications that may arise with the use of this kindof therapy and existing studies, however, are lacking in demon-
strating the efﬁcacy of recombinant tissue plasminogen activa-
tors particularly intrapleural TNKase administration. Thus,
the objective of this study is to determine the safety and efﬁ-
cacy of TNKase for the treatment of loculated parapneumonic
pleural effusions and thoracic empyema after failure of com-
plete drainage of pigtail catheter.
Patients and methods
This study was done at the Respirology and Interventional
Radiology Departments, Farwaniya Hospital, Alrashid Respi-
ratory centre and Thoracic Surgery Department, Chest Hospi-
tal, Ministry of Health, State of Kuwait, between January 2012
and November 2013. 58 patients were admitted with loculated
pleural effusions {22 patients (37.9%) with thoracic empyema
and 36 patients (62.1%) with complicated parapneumonic
effusion (parapneumonic effusion was deﬁned as an effusion
associated with bacterial pneumonia [12]}. All patients
received intrapleural TNKase after unfulﬁlled drainage using
a pigtail catheter (<70 mL for the last 24 h) [13], which was
inserted under chest ultrasound guidance after exclusion of
pigtail catheter blockage, kinking or improper positioning.
More than one catheter can be used to help drain off anatom-
ically discrete loculations [14].
All patients were subjected to all of the following: complete
history taking, thorough general and local examination, labo-
ratory investigations including CBC, ESR, CRP, and pleural
ﬂuid analysis, cultures and cytology, plain chest X-ray and
computed tomography scan. Hematological studies including
hemoglobin, platelet count, prothrombin time (PT), interna-
tional normalized ratio (INR), and activated partial thrombo-
plastin time (APTT) were taken very early in the morning,
every day, before every dose of TNKase instillation [14].
Thoracic empyema (existence of intrapleural frank pus) and
complicated parapneumonic effusions (CPE) were deﬁned
according to American College of Chest Physicians (ACCP)
classiﬁcation [15] of parapneumonic effusions after pleural
ﬂuid analysis (Table 1), using Light’s criteria [16] all pleural
ﬂuid was exudative in nature (deﬁned as any combination of
pleural/serum protein >0.5, pleural lactate dehydrogenase
(LDH) level >200 U/L, or pleural/serum LDH level >0.6),
with underlying lung infection based on both clinical and
radiological evidence of active lung infections, i.e., fever,
productive cough with consolidation and loculations with
obvious septations conﬁrmed by Chest ultrasound (US) and/or
chest computed tomography (CT). Ultrasound detects pleural
ﬂuid septations with greater sensitivity than CT, (Table 2)
[17]. Patients with other loculated malignant or tuberculous
Table 2 Pleural ﬂuid sonographic appearances.
Sonographic
Appearance
Signiﬁcance
Anechoic (black
ﬂuid)
Transudative or
exudative eﬀusion
Septated (multiple
lines within ﬂuid)
Exudative eﬀusion;
may suggest possible
diﬃculties inserting
chest tube; eﬀusion
may drain poorly,
although not
necessarily
Echogenic (echoes,
often swirling,
within ﬂuid)
Exudative eﬀusion;
heavily echogenic
ﬂuid suggestive of
blood or pus
Table 1 American College of Chest Physicians classiﬁcation of parapneumonic effusions.
Eﬀusion stage Pleural space
anatomy
Pleural ﬂuid
bacteriology
Pleural ﬂuid
chemistry
Category Risk of
poor
outcome
Drainage Additional
ﬁbrinolytic,
VATS or
surgery
required
I (uncomplicated
parapneumonic)
A0: Minimal,
free-ﬂowing
eﬀusion (<10
mm on lateral
decubitus)
AND BX:
Culture and
Gram
stain results
unknown
AND
CX: pH
unknown
1 Very low No No
II (uncomplicated
parapneumonic)
A1: Small-to-
moderate free-
ﬂowing
eﬀusion (>10
mm and <1/2
hemithorax)
AND B0:
Negative
culture and
Gram stain
AND
C0: pH P7.2
2 Low No No
III (complicated
parapneumonic)
A2: Large, free-
ﬂowing eﬀusion
(P1/2
hemithorax),
loculated eﬀusion
or
eﬀusion with
thickened pleura
OR B1:
Positive
culture or
Gram stain
OR
C1: pH <7.2
3 Moderate Yes Yes
IV (empyema) B2: Pus 4 High Yes Yes
Intrapleural Tenecteplase therapy 915effusions were excluded as proved by ﬂuid, microbiology,
cytology and/or pleural biopsy.
Once the patient is best positioned for the procedure, chest
US was used to determine the optimal needle route to the effu-
sion, without any intervening lung on the planned approach.
The movement of the lung should be viewed through a maxi-
mal respiratory cycle. A speciﬁc pigtail catheter kit (8–10 Fr),
(Fig. 1) was used which, has the beneﬁt of a plastic catheter
that can be advanced over a metal trocar. Removing the metal
trocar immediately as the pleural effusion is entered, while
simultaneously advancing the ﬂexible plastic catheter, will
have the beneﬁt of decreasing the risk of injury to the lung.
The pigtail catheter was placed in the largest loculation and
attached to a water-sealed system. Flushing with 15 cc ofisotonic normal saline solution 0.9% was done. Drainage
was recorded every 8 h (Figs. 2 and 3).
TNKase (Metalyse, Boehringer Ingelheim, Germany) was
administered intrapleurally on a daily basis with maximum
5 doses, as a solution of 15 mg TNKase in 100 mL of 0.9%
saline solution via three-way stopcock valve connected to
the pigtail catheter using a 50 cc syringe. The stopcock valve
was subsequently closed for 3 h and the patient was rotated
in various positions to disperse the drug. Subsequently, the
stopcock was opened to 20 mm Hg suction over an under-
water seal device. TNKase was reinstilled, if on repeat chest
X-ray, US and/or CT scan, signiﬁcant persistent pleural effu-
sion was found 24 h after the previous instillation. Pigtail
catheter was removed after the total ﬂuid drainage was less
than 70 mL in 24 h after subtraction of amount of ﬂushed
saline [18,19].
The effectiveness of TNKase was assessed by (1) the per-
centage of patients achieving complete or near complete drain-
age of loculated pleural effusion as determined by the volume
of ﬂuid drained from the chest tube daily, via serial chest X-ray
and chest US and/or CT scan during the ﬁve days of intrapleu-
ral therapy, (2) the clinical outcome (resolution of symptoms
of infection and pleural effusion including, fever and raised
white blood count and CRP), (3) hemorrhagic complications
associated with catheter drainage [20]. Failure was deﬁned as
the (1) failure to resolve loculated effusion (no improvement
or worsening in the imaging, manifested by an increase in pleu-
ral ﬂuid volume or appearance of new air-ﬂuid levels) or (2)
complication necessitating intervention (speciﬁcally bleeding
that necessitates ﬂuid resuscitation and/or further interven-
tion). Decision to continue TNKase instillation or to proceed
to VATS or surgical drainage was taken on the basis of clinical
and radiological judgment and signs of sepsis [21].
Figure 1 (A) Pigtail catheter kit components. (B) Pigtail catheter loaded and ready for use. (C) Pigtail inside pleural cavity after
intrapleural TNKase instillation with complete drainage. (D) Pigtail inside pleural cavity after TNKase with accepted drainage.
0 
10
20
30
40
50
60
70
80
90
Thoracic Empyema Parapneumonic Eﬀusions
Pe
rc
en
ta
ge
 o
f c
as
es
 %
Successful 
Failed
Figure 2 Successful outcome after TNKase treatment for cases
with loculated parapneumonic effusions and thoracic empyema.
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All patients with one of the following were excluded from the
study [22]
 Other causes of pleural effusion (malignancy, tuberculosis,
or hemothorax).
 Active internal bleeding, involving intracranial and retro-
peritoneal sites, or the gastrointestinal, genitourinary, or
respiratory tracts.
 History of stroke within 3 months.
 Intracranial neoplasm, arteriovenous malformation, or
aneurysm.
 Uncorrectable bleeding diathesis (INR >1.5 despite
therapy). Recent intracranial or intraspinal surgery or head trauma
within 14 days.
 Pregnancy (positive pregnancy test).
 Severe uncontrolled hypertension.
 Major thoracic or abdominal surgery within 10 days of
admission.
 Known allergy to TNKase.
Statistical analysis
Data were collected using a pre-designed data entry sheet.
Analysis was done using statistical software ‘SPSS version
10.0’ (SPSS Inc, Chicago, IL, USA). Normally distributed
variables were summarized as mean with standard deviation
and compared using Student’s t-test. X2 or Fisher exact test
was applied to compare the categorical variables. A binary
multivariate logistic model was used to identify factors associ-
ated with increased risk of bleeding. For all analyses, P value
<0.05 was considered statistically signiﬁcant and P value
<0.001 was considered highly statistically signiﬁcant.Results
This study was done on 58 patients with encysted parapneu-
monic effusions (38 patients, 65.5%) and thoracic empyema
(20 patients, 34.5%). All patients were not drained completely
using pigtail catheter therapy and eligible for intrapleural
TNKase therapy. Thirty-eight (65.5%) of all patients were
male, with total mean age of 49.6 ± 16 years. The overall
intrapleural TNKase effectiveness in achieving complete
Figure 3 Successful outcome after TNKase treatment for each
dose.
Intrapleural Tenecteplase therapy 917drainage of pleural collections was 49 of 58 cases (84.5%).
Intrapleural TNKase was successful in 70% (14 of 20 patients)
of patients with thoracic empyema, and 92.1% (35 of 38
patients) of parapneumonic effusions (Fig. 1). Of 49 patients
with successful outcome, 8 patients (13.8%) had residual mild
pleural processes (<10% of hemithorax), and accepted as suc-
cessively treated cases. Only nine patients (15.5%) failed to
respond, 8 of them showed thick ﬁbrous peel with lung entrap-
ment, and multiloculated effusion despite full 5 doses of intra-
pleural TNKase. One case was only marked as failure due to
uncontrollable tube bleeding. All failed cases were sent for
VATS with debridement and surgical chest tube placement.
With follow up, these cases ﬁnally had complete resolution
of their collections with no mortality.
Tables 3 and 4 show that there were no signiﬁcant differ-
ences between cases responding to intrapleural TNKase ﬁbri-
nolytic therapy and non-responders regarding clinical or
laboratory characteristics or associated comorbidities before
starting the therapy, (all P> 0.05). In successfully-treated
cases with CPE (35 of 38 (92.1%), there was a highly signiﬁ-
cant difference between the mean duration of fever beforeTable 3 Baseline demographic and clinical characteristics between
Total (58 cases) CPE
38 (6
S= 49 (84.5%) F= 9 (15.5%) S
No. (%) 35 (9
Age (mean ± SD) (T= 49.6 ± 16) 48 ±
Sex (M/F) (T= 38/20) 26/9
Current smoker 9 (25
Co-morbidity no. (%) COPD 3 (8.8
CVD 5 (14
DM 4 (11
Hepatic diseases 3 (8.8
Renal disease 4 (11
Duration of symptoms before inclusion (days), mean ± SD 6.6 ±
Fever >38.5 C, n (%) 28 (8
Dyspnea, n (%) 26 (7
Cough, n (%) 34 (7
Sputum production, n (%) 24 (6
Chest pain, n (%) 27 (7and after TNKase instillation (8.6 ± 3.5 days and
2.1 ± 5.0 days respectively) (P< 0.001). Other parameters
measured also decreased signiﬁcantly after TNKase instilla-
tion, the mean values ± SD of WBC and CRP before TNKase
instillation were WBC; 14,322 ± 8625 per mm3 and CRP;
92.48 ± 3.4 mg/dL and WBC; 7106 ± 1526 per mm3 and
CRP; 4.22 ± 4.1 mg/dL after TNKase instillation. Also, in
successfully-treated cases of with TE (14 of 20 (70%), there
was a highly signiﬁcant difference between the mean duration
of fever before and after TNKase instillation (10.0 ± 6.3 days
and 3.2 ± 8 days respectively) (P< 0.001). Other parameters
measured also decreased signiﬁcantly after TNKase instilla-
tion, the mean values ± SD of WBC and CRP before TNKase
instillation were WBC; 16,108 ± 4398 per mm3 and CRP;
130.22 ± 10.6 mg/dL and WBC; 8208 ± 3268 per mm3 and
CRP; 8.15 ± 2.08 mg/dL after TNKase instillation (all
P< 0.05, Table 5).
Table 5 shows that there was a highly signiﬁcant increase in
the total mean pleural ﬂuid drainage before and after instilla-
tion of TNKase. Before TNKase, the pleural ﬂuid ranged from
120 to 1830 mL with a mean of 623 ± 54 mL. On the other
hand, the mean total ﬂuid drained after TNKase instillation
was 2350 ± 874 mL (range 1100–4200), (P< 0.001). In cases
with encysted empyema, the pleural ﬂuid ranged from 150 to
1650 mL with a mean of 420 ± 74 mL and after TNKase
instillation, the mean total ﬂuid drained was 2088 ± 502 mL
(range 950–3800), (P< 0.001). The total number of TNKase
instillations ranged from 2 to 5 (mean, 3.2). Fig. 4 shows that
the highest mean of pleural drainage was after the 3rd dose in
all treated patients.
In responders with loculated CPE, the mean percentage of
pleural ﬂuid occupation of the chest X-ray (CXR) was
29 ± 2.3 before TNKase administration. This occupation
was highly signiﬁcantly improved to 5 ± 1.2 after TNKase
administration (P< 0.001, Table 5). Also, the successfully
treated patients with TE, 14 (75%) have signiﬁcantly improved
their CXR after occupation administration (shadow <10% of
hemithorax) after TNKase administration (25.5 ± 4.3 vs
8.0 ± 2.8, P< 0.05), Table 4. The loculated collections
were demonstrated only in 52 of 58 patients (89.7%) at CTsuccessful and failed treated patients before TNKase instillation.
5.5%)
TE
20 (34.5%)
F P value S F P value
2.1) 3 (7.9) – 14 (70) 6 (30) –
40 50 ± 18 >0.05 46 ± 09 51 ± 43 >0.05
2/1 >0.05 6/8 4/2 >0.05
.7) 1 (33.3) >0.05 3 (21.4) 2 (33.3) >0.05
) 0 (0) >0.05 2 (14.3) 3 (50) >0.05
.3) 1 (33.3) >0.05 2 (14.3) 1 (16.7) >0.05
.4) 0 (0) >0.05 3 (21.4) 3 (50) >0.05
) 0 (0) >0.05 1 (7.1) 2 (12.5) >0.05
.4) 1 (33.3) >0.05 2 (14.3) 3 (50) >0.05
3.5 8.1 ± 5.0 >0.05 9.1 ± 5.9 8 ± 2.1 >0.05
0) 2 (66.7) >0.05 10 (71.4) 4 (66.7) >0.05
4.2) 3 (100) >0.05 11 (78.8) 5 (83.3) >0.05
9.1) 2 (66.7) >0.05 13 (92.9) 6 (100) >0.05
8.6) 3 (100) >0.05 8 (57.1) 3 (50) >0.05
7.1) 2 (66.7) >0.05 10 (71.4) 5 (83.3) >0.05
Table 4 Baseline laboratory and radiological characteristics between successful and failed treated patients before TNKase instillation.
TE
20 (34.5%)
CPE
38 (65.5%)
TE
20 (34.5%)
S= 49 (84.5%) F= 9 (15.5%) S F P value S F P value
No. (%) 35 (92.1) 3 (7.9) – 14 (70) 6 (30) –
Pleural Fluid pH, mean ± SD 7.0 ± 0.4 6.8 ± 0.5 >0.05 6.9 ± 0.1 6.8 ± 0.3 >0.05
LDH/IU/L (>1000 U), No. (%) 25 (65.8) 2 (75) >0.05 14 (100) 6 (100) >0.05
Glucose (<40 mg/dL), No. (%) 28 (68.4) 2 (75) >0.05 14 (100) 6 (100) >0.05
WBC (>1000 mm3), No. (%) 26 (68.4) 3 (100) >0.05 9 (64.3) 4 (66.7) >0.05
US septations, No. (%)
total: 37 (63.8)
20 (57.1) 3 (100) <0.05 8 (57.1) 6 (100) <0.05
CT loculations, No. (%)
total: 52 (89.7%)
32 (65.7) 3 (100) >0.05 12 (85.7) 5 (83.3) >0.05
CT pleural thickness mm, mean ± SD 6.2 ± 4.3 7.8 ± 0.4 >0.05 5.2 ± 1.9 5.8 ± 6 >0.05
Table 5 Indicators of outcome before and after TNKase instillation in successfully-treated patients.
Successful cases = 49 (84.5%)
CPE
35 (92.1%)
TE
14 (70%)
Before After P value Before After P value
Duration of fever/days (mean ± SD) 8.6 ± 3.5 2.1 ± 5 <0.001 10.0 ± 6.3 420 ± 74 <0.001
White cell count/mm3 (mean ± SD) 14,322 ± 8625 7106 ± 1526 <0.05 16,108 ± 4398 8208 ± 3268 <0.05
CRP (mg/dL mean ± SD) 92.48 ± 3.4 4.22 ± 4.1 <0.05 130.22 ± 10.6 8.15 ± 2.08 <0.05
Pleural ﬂuid drained amount mL (mean ± SD) 623 ± 54 2350 ± 874 <0.001 420 ± 74 2088 ± 502 <0.001
% area occupied by eﬀusion on CXR (mean ± SD) 29 ± 2.3 5 ± 1.2 <0.001 420 ± 74 8 ± 2.8 <0.05
CT loculations, No. (%) 32 (65.7) 5 (14.3) <0.05 420 ± 74 3 (21.4) <0.05
Figure 4 Mean amounts of pleural ﬂuid drainage before and
after TNKase treatment for each dose.
918 A. Refaat et al.assessment; each of these patients had one to ﬁve (mean, 2.2)
separate pockets. Six patients had single collections that
appeared to layer but drained incompletely after pigtail cathe-
ter placement. Table 4 showed that the number of pockets was
not a signiﬁcant predictor of TNKase effectiveness. However,
after TNKase administration, there was a signiﬁcant improve-
ment in the number of loculations in all successful cases
(P< .005, Table 5). In all cases, the maximum pleural thick-
ness ranged from 1 to 17 mm (mean, 5.4 ± 2.0 mm). In
patients successfully treated with CPE, pleural thickness ran-
ged from 1.2 to 12.7 mm with mean 6.2 ± 4.3 mm and for
patients in whom TNKase failed, pleural thickness ranged
from 1.2 to 14.9 mm with mean 7.8 ± 0.4 with insigniﬁcant
difference between these two groups (P> 0.05). On theother hand, in patients successfully treated with TE, pleural
thickness ranged from 1.1 to 14.6 mm with mean
5.2 ± 1.9 mm. For patients in whom TNKase failed, pleural
thickness ranged from 1.2 to 17.0 mm with mean 5.8 ± 6.
Mean pleural thickness did not differ signiﬁcantly between
these two groups (P> 0.05).
There were no complications at the time of catheter place-
ment. Major pleural hemorrhages were occurring with intra-
pleural TNKase in only four cases (6.9%) {CPE in one
(1.7%) and TE in three (5.2%)} and the ﬁbrinolytic therapy
was stopped immediately. Hemorrhage occurred 1–2 days
after TNKase initiation. Two of bled patients had end-stage
renal disease on regular haemodialysis and the other two
patients were on infantile dose of aspirin and systemic antico-
agulation before TNKase therapy. In these patients, the indi-
cators of hemorrhage were blood in the collection chamber
with an associated hemoglobin decrease and worsening of
chest radiograph. All hemorrhagic complications required
blood transfusion (2–4 units of packed red blood cells).
Patients were revaluated after cessation of bleeding. Two of
them eventually drained successively via same pigtail cathe-
ters and other two patients required VATS. Thus, intrapleu-
ral TNKase was successful in clearing a pleural effusion even
in the setting of new hemorrhage in 50% (two of four) of
patients. All patients who bled survived. No other complica-
tions occurred. No systemic hemorrhage was documented in
any patient.
Binary analysis did not demonstrate increased bleeding
with studied levels of international normalized ratio,
Table 6 Risk factors for bleeding in all treated patients.
INR 1.2 ± 0.4
PT 15.3 ± 3.8
APTT 35.2 ± 9.5
Platelets 305.6 ± 152.1
Antithrombotics None 41 (70.1%)
Aspirin 13 (22.4%)
Clopidogrel 3 (5.2%)
Warfarin 4 (6.9%)
Dabigatran 3 (5.2%)
SC heparin 2 (3.4%)
Heparin infusion 3 (5.2%)
Enoxaparin 8 (13.8%)
Binary analysis did not demonstrate increased bleeding with above
all variables (P> 0.05).
Intrapleural Tenecteplase therapy 919prothrombin time, partial thromboplastin time and platelets,
or those received antithrombotic drugs before TNKase
instillation (Table 6). All four hemorrhages occurred in the
setting of normal-range of coagulation proﬁle. Of all included
patients, four were receiving warfarin, eight were receiving
enoxaparin, and ﬁve were receiving unfractionated heparin,
two were receiving prophylactic SC heparin and 3 patients
received heparin infusion. The increased bleeding risk in
patients with therapeutic anticoagulation compared with that
occurred in patients not receiving any anticoagulation was
statistically insigniﬁcant (P< 0.05). Three of the all patients
were receiving clopidogrel, and neither of them bled even
though one of them was receiving simultaneous intravenous
heparin. Twelve patients were receiving aspirin, six of them
were receiving both systemic anticoagulation and aspirin,
and two of these six bled.
All patients tolerated well the pigtail drainage procedures
and instillation of TNKase. Adverse reactions after TNKase
administration were mild and did not affect the TNKase
administration, including mild discomfort and dull pain during
instillation in 7 patients (12.1%), which was easily managed
with analgesic therapy. Mild local hemorrhage occurred in 3
patients (5.2%. Other minor complications include shortness
of breath requiring an increase in their oxygen requirement
(3 cases, 5.2%) and fever (>38 C) requiring antipyretics (2
cases, 3.4%). No systemic adverse effects of TNKase were
recorded, i.e., allergic reaction, hypotension and no signiﬁcant
changes in the coagulation proﬁle of the patients were
observed, including the patients who presented pleural hemor-
rhage after TNKase administration. All patients successfully
treated with TNKase had no recurrences and were doing well
at the time of discharge.
Discussion
Loculated empyema and parapneumonic effusions cause con-
siderable morbidity and mortality, with an estimated case-
fatality rate of 15% [1]. Many patients require surgical inter-
vention to drain the infected pleural space. Intrapleural admin-
istration of ﬁbrinolytic agents has also been widely employed
to lyse the ﬁbrinous structures of multiloculated pleural space.
Based on early reports of efﬁcacy, the British Thoracic Society
(BTS) [23,24] and the ACCP guidelines [15] recommend ﬁbri-
nolytic drugs as management options.The current study evaluated the effectiveness and risk fac-
tors for complications with the administration of intrapleural
Tenecteplase (TNKase). We found that Tenecteplase adjunc-
tive to pigtail catheter drainage signiﬁcantly improves the out-
come of medically treated complicated parapneumonic
effusions and thoracic empyema, which led to a reduced need
for surgical referral. Our total success rate was 84.5% (49/58
patients). The amount of the pleural ﬂuid drained was signiﬁ-
cantly improved after TNKase instillation, resulting in a signif-
icant improvement of the chest X-ray and CT loculations.
Also, we noted a rapid and signiﬁcant decrease of inﬂamma-
tory parameters such as WBC and CRP, after intrapleural
administration of TNKase. This beneﬁt was achieved without
systemic ﬁbrinolysis or systemic hemorrhage.
Several investigators have studied the efﬁcacy and safety of
intrapleural t-PA in the treatment of pleural effusion and
empyema [21,22]. These researchers report a success outcome
deﬁned as improvement of symptoms and X-ray imaging with-
out need for surgical intervention. They used alteplase in place
of streptokinase. Alteplase is a direct plasminogen activator,
compared with streptokinase, which is indirect. As a result,
plasminogen ﬁrst binds with streptokinase to form an activator
complex, which then converts plasminogen to plasmin,
whereas alteplase directly converts plasminogen to plasmin.
This difference may theoretically lower the levels of plasmino-
gen in the case of streptokinase and make it less efﬁcacious
compared with placebo.
Walker et al. [25] ﬁrst reported the apparent beneﬁts of alte-
plase in a case with a multi-loculated pleural effusion as an
adjunct to chest tube drainage and antibiotics. Subsequently,
Skeete et al. [26] instilled t-PA through surgical chest tubes into
42 patients with a variety of pleural conditions, of which 12
were empyemas. They reported accelerated radiological
improvement and clinical beneﬁt. Levinson and Pennington
[27] used t-PA for 20 patients with largely multiloculated pleu-
ral infections; they concluded that t-PA in combination with
careful image-guided placement of chest tubes is highly effec-
tive in resolving the effusion and curing the infection. Froud-
arakis et al. [18] found that intrapleural instillation of r-TPA
at a dose of 25 mg is a well-tolerated and effective treatment
in 95% of adult patients with complicated parapneumonic
effusion and empyema. The mean volume of ﬂuid, in their
study, increased signiﬁcantly after r-TPA administration and
WBC and CRP were signiﬁcantly improved after r-TPA instil-
lations. In the study by Gervais et al. [28] 25 patients, with
empyemas and complicated parapneumonic effusions, were
selected for ﬁbrinolysis with incomplete initial pleural ﬂuid
drainage. The overall success rate was 86% based on CT imag-
ing studies obtained before chest tube insertion that demon-
strated multiple locules. The authors concluded that rtPA
successfully drained effusions that would otherwise have
required surgery. Ben-Or et al. [21] have recently used alteplase
to treat different complex pleural processes with an overall suc-
cess rate of 86.4%. They reported that one to two doses was
the most successful. Even so, in the MIST II [10] and of Rah-
man et al. [11] trials the intrapleural t-PA–DNase therapy sig-
niﬁcantly improved ﬂuid drainage in patients with pleural
infection and reduced the frequency of surgical referral and
the duration of the hospital stay. However, the treatment with
t-PA alone was ineffective. Komissarov et al. [29] reported that
plasminogen exhaustion can explain these results and advised
to assess intrapleural plasminogen and plasminogen activator
920 A. Refaat et al.inhibitors-1 prior to intrapleural ﬁbrinolytic injection in order
to optimize the outcome.
Regarding the ability of imaging studies to predict the suc-
cess or failure of ﬁbrinolytic therapy, our study showed that
the number of pockets on CT and the percentage of pleural
ﬂuid occupation on plain chest X-ray were not a signiﬁcant
predictor of TNKase effectiveness. On the other hand, the
presence of US septations was signiﬁcantly affecting response
of intrapleural ﬁbrinolysis. Heterogeneity was present between
studies as regards the type of the imaging modality used to pre-
dict the pleural ﬂuid resolution. In MIST1 [9] study, radio-
graphic improvement was assessed solely using chest
radiographs and not ultrasonography or CT imaging. The
appearance of infected collections on chest radiograph
depends on the volume and viscosity of pleural ﬂuid, the posi-
tion of the patient, and the presence of loculations. Limitations
of chest radiograph include difﬁculties in assessing subpulmon-
ic effusions, nondependent loculations, and loculations along
the mediastinal pleural reﬂections. Ultrasound imaging, better
than CT imaging, allows characterization of pleural ﬂuid col-
lections with septations; however, CT imaging is better for
characterizing loculated effusions in interlobar ﬁssures or adja-
cent to the mediastinum [30]. In compatible with our results,
Gervais et al., [28] reported that CT scan features of number
of loculations, degree of pleural thickening (range 1–15 mm),
or pleural heterogeneity did not predict ultimate outcome for
patients treated with intrapleural recombinant tissue plasmin-
ogen activator. Similarly, Levinson and Pennington [27] noted
no differences in outcomes between patients with single or
multiple loculations treated with intrapleural urokinase or
recombinant tissue plasminogen activator. Chen et al. [31]
investigated the outcomes of patients who had been diagnosed
with empyema and CPE and had received ultrasound-guided
small-bore catheter drainage. The appearance of sonographic
septation is a useful sign to help predict the outcome of these
patients.
The most frightened complication of intrapleural ﬁbrinolyt-
ics is bleeding, pleural hemorrhages were occurring in our
study after intrapleural TNKase in only four cases (6.9%),
which occurred 1–2 days after TNKase initiation. The inci-
dence of bleeding after intrapleural ﬁbrinolytics in the litera-
ture ranges between 2% and 15%. This wide range could be
explained by differences in patient’s selection and type of ﬁbri-
nolytic used. In the MIST II trial [10], Rahman and Maskell
report on ﬁve cases of bleeding, including two cases of intra-
pleural bleeding and one case of haemoptysis that occurred
in the tPA and DNase arm (5.76%). Gervais et al., [28] found
that systemic anticoagulation does not increase bleeding risk
with intrapleural tPA, but therapeutic anticoagulation is asso-
ciated with a signiﬁcantly increased risk of pleural hemor-
rhage. e arm (5.76%). In one recent study of Abu-Daff
et al., [14] bleeding occurred in 15 of 227 (6.6%) of their
patients. However, three cases required emergency thoracot-
omy for bleeding, resulting in haemodynamic instability, of
which one patient died. Notably, both t-PA and streptokinase
were used in this study. This study had some limitations; it is a
retrospective study and represented a heterogeneous group of
patients with a selection bias. Although we could not identify
any speciﬁc variable in our study to be statistically associated
with bleeding, we did note a trend towards the concomitant
use of aspirin as antiplatelet medication with 22.4% of our
patients receiving this medication.Conclusion
Intrapleural TNKase is an effective therapy in improving
drainage of loculated parapneumonic effusions and thoracic
empyema not drained with pigtail catheters alone and can
prevent surgical interventions. Intrapleural TNKase is well
tolerated with infrequent adverse events.Conﬂict of interest
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